-
Je něco špatně v tomto záznamu ?
The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe
A. Mocroft, A. Geressu, C. Beguelin, JM. Llibre, JV. Lazarus, J. Tomazic, J. Smidt, M. Parczewski, J. Brännström, D. Sedlacek, O. Degen, M. van der Valk, D. Paduta, L. Flamholc, P. Schmid, C. Orkin, LN. Nielsen, C. Hoffmann, M. Beniowski, C....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Odkazy
PubMed
36476454
DOI
10.1097/qad.0000000000003406
Knihovny.cz E-zdroje
- MeSH
- Hepacivirus MeSH
- HIV infekce * komplikace MeSH
- konečné stadium selhání jater * MeSH
- lidé MeSH
- RNA MeSH
- virus hepatitidy B MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: There are limited data on end-stage liver disease (ESLD) and mortality in people with HIV (PWH) coinfected with both hepatitis B virus (HBV) and hepatitis C virus (HCV). METHODS: All PWH aged greater than 18 under follow-up in EuroSIDA positive for HBsAg (HBV), and/or HCVRNA+, were followed from baseline (latest of 1 January 2001, EuroSIDA recruitment, known HBV/HCV status) to ESLD, death, last visit, or 31 December 2020. Follow-up while HCVRNA- was excluded. In two separate models, Poisson regression compared three groups updated over time; HIV/HBV, HIV/HCV, and HIV/HBV/HCV. RESULTS: Among 5733 included individuals, 4476 (78.1%) had HIV/HCV, 953 (16.6%) had HIV/HBV and 304 (5.3%) had HIV/HBV/HCV. In total, 289 (5%) developed ESLD during 34 178 person-years of follow-up (PYFU), incidence 8.5/1000 PYFU [95% confidence interval (CI) 7.5-9.4] and 707 deaths occurred during 34671 PYFU (incidence 20.4/1000 PYFU; 95% CI 18.9-21.9). After adjustment, compared with those with HIV/HCV, persons with HIV/HBV had significantly lower rates of ESLD [adjusted incidence rate ratio (aIRR) 0.53; 95% CI 0.34-0.81]. Those with HIV/HBV/HCV had marginally significantly higher rates of ESLD (aIRR 1.49; 95% CI 0.98-2.26). Those under follow-up in 2014 or later had significantly lower rates of ESLD compared with 2007-2013 (aIRR 0.65; 95% CI 0.47-0.89). Differences in ESLD between the three groups were most pronounced in those aged at least 40. After adjustment, there were no significant differences in all-cause mortality across the three groups. CONCLUSION: HIV/HBV-coinfected individuals had lower rates of ESLD and HIV/HBV/HCV had higher rates of ESLD compared with those with HIV/HCV, especially in those aged more than 40. ESLD decreased over time across all groups. CLINICALTRIALSGOV IDENTIFIER: NCT02699736.
Barcelona Institute for Global Health Hospital Clínic University of Barcelona Barcelona Spain
Carol Davila University of Medicine and Pharmacy Bucharest
Charles University Hospital Plzen Plzen Czech Republic
Department of Infectious Diseases Ljubljana University Medical Center Ljubljana Slovenia
Division of Infectious Diseases Cantonal Hospital St Gallen St Gallen Switzerland
Gomel Regional Centre for Hygiene Gomel Belarus
Hospital Universitari Germans Trias i Pujol Department of Infectious Diseases Badalona
ICH Study Center Hamburg Hamburg Germany
Narva AIDS Centre Kohtla Järve Estonia
Nordsjællands Hospital Hillerød Denmark
Outpatients clinic for diagnostics and Therapy for AIDS Specialistic Hospital Chorzów Poland
Royal Lancaster Infirmary Lancaster UK
Royal London Hospital London UK
Skåne University Hospital Malmö Sweden
University Clinic Hamburg Eppendorf Hamburg Germany
University Hospital for Infectious Diseases 'Dr Fran Mihaljević' Zagreb Croatia
Victor Babes Clinical Hospital for Infectious and Tropical Diseases Bucharest Romania
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032004
- 003
- CZ-PrNML
- 005
- 20230131150940.0
- 007
- ta
- 008
- 230120s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/QAD.0000000000003406 $2 doi
- 035 __
- $a (PubMed)36476454
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Mocroft, Amanda $u CHIP, Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark $u Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London
- 245 14
- $a The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe / $c A. Mocroft, A. Geressu, C. Beguelin, JM. Llibre, JV. Lazarus, J. Tomazic, J. Smidt, M. Parczewski, J. Brännström, D. Sedlacek, O. Degen, M. van der Valk, D. Paduta, L. Flamholc, P. Schmid, C. Orkin, LN. Nielsen, C. Hoffmann, M. Beniowski, C. Oprea, J. Begovac, L. Peters
- 520 9_
- $a BACKGROUND: There are limited data on end-stage liver disease (ESLD) and mortality in people with HIV (PWH) coinfected with both hepatitis B virus (HBV) and hepatitis C virus (HCV). METHODS: All PWH aged greater than 18 under follow-up in EuroSIDA positive for HBsAg (HBV), and/or HCVRNA+, were followed from baseline (latest of 1 January 2001, EuroSIDA recruitment, known HBV/HCV status) to ESLD, death, last visit, or 31 December 2020. Follow-up while HCVRNA- was excluded. In two separate models, Poisson regression compared three groups updated over time; HIV/HBV, HIV/HCV, and HIV/HBV/HCV. RESULTS: Among 5733 included individuals, 4476 (78.1%) had HIV/HCV, 953 (16.6%) had HIV/HBV and 304 (5.3%) had HIV/HBV/HCV. In total, 289 (5%) developed ESLD during 34 178 person-years of follow-up (PYFU), incidence 8.5/1000 PYFU [95% confidence interval (CI) 7.5-9.4] and 707 deaths occurred during 34671 PYFU (incidence 20.4/1000 PYFU; 95% CI 18.9-21.9). After adjustment, compared with those with HIV/HCV, persons with HIV/HBV had significantly lower rates of ESLD [adjusted incidence rate ratio (aIRR) 0.53; 95% CI 0.34-0.81]. Those with HIV/HBV/HCV had marginally significantly higher rates of ESLD (aIRR 1.49; 95% CI 0.98-2.26). Those under follow-up in 2014 or later had significantly lower rates of ESLD compared with 2007-2013 (aIRR 0.65; 95% CI 0.47-0.89). Differences in ESLD between the three groups were most pronounced in those aged at least 40. After adjustment, there were no significant differences in all-cause mortality across the three groups. CONCLUSION: HIV/HBV-coinfected individuals had lower rates of ESLD and HIV/HBV/HCV had higher rates of ESLD compared with those with HIV/HCV, especially in those aged more than 40. ESLD decreased over time across all groups. CLINICALTRIALSGOV IDENTIFIER: NCT02699736.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a virus hepatitidy B $7 D006515
- 650 _2
- $a Hepacivirus $7 D016174
- 650 12
- $a konečné stadium selhání jater $7 D058625
- 650 _2
- $a RNA $7 D012313
- 650 12
- $a HIV infekce $x komplikace $7 D015658
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Geressu, Adam $u Royal Lancaster Infirmary, Lancaster, UK
- 700 1_
- $a Beguelin, Charles $u Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 700 1_
- $a Llibre, Josep M $u Hospital Universitari Germans Trias i Pujol, Department of Infectious Diseases, Badalona
- 700 1_
- $a Lazarus, Jeffrey V $u Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain
- 700 1_
- $a Tomazic, Janez $u Department of Infectious Diseases, Ljubljana University Medical Center, Ljubljana, Slovenia
- 700 1_
- $a Smidt, Jelena $u Narva AIDS Centre, Kohtla-Järve, Estonia
- 700 1_
- $a Parczewski, Milosz $u Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Szczecin, Poland
- 700 1_
- $a Brännström, Johanna $u Department of Infectious Diseases/Venhälsan, Södersjukhuset and Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Sedlacek, Dalibor $u Charles University Hospital Plzen, Plzen, Czech Republic
- 700 1_
- $a Degen, Olaf $u University Clinic Hamburg Eppendorf, Hamburg, Germany
- 700 1_
- $a van der Valk, Marc $u Stichting hiv monitoring $u Amsterdam University Medical Centers, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands
- 700 1_
- $a Paduta, Dzmitry $u Gomel Regional Centre for Hygiene, Gomel, Belarus
- 700 1_
- $a Flamholc, Leo $u Skåne University Hospital, Malmö, Sweden
- 700 1_
- $a Schmid, Patrick $u Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
- 700 1_
- $a Orkin, Chloe $u Royal London Hospital, London, UK
- 700 1_
- $a Nielsen, Lars N $u Nordsjællands Hospital, Hillerød, Denmark
- 700 1_
- $a Hoffmann, Christian $u ICH Study Center Hamburg, Hamburg, Germany
- 700 1_
- $a Beniowski, Marek $u Outpatients clinic for diagnostics and Therapy for AIDS, Specialistic Hospital, Chorzów, Poland
- 700 1_
- $a Oprea, Cristiana $u Carol Davila University of Medicine and Pharmacy, Bucharest $u Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania
- 700 1_
- $a Begovac, Josip $u University Hospital for Infectious Diseases 'Dr Fran Mihaljević', Zagreb, Croatia
- 700 1_
- $a Peters, Lars $u CHIP, Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
- 773 0_
- $w MED00000179 $t AIDS (London, England) $x 1473-5571 $g Roč. 37, č. 1 (2023), s. 91-103
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36476454 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150936 $b ABA008
- 999 __
- $a ok $b bmc $g 1891030 $s 1183339
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 37 $c 1 $d 91-103 $e 20221018 $i 1473-5571 $m AIDS $n AIDS $x MED00000179
- LZP __
- $a Pubmed-20230120
